Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

5 terminated/withdrawn out of 10 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results4 withdrawn

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 1

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(2)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03873168Terminated

Post-Market Evaluation of HEMOBLAST™ Bellows in Open Gynecological, Urological, ENT, Head, Neck, and Vascular Surgeries

Role: lead

NCT04471350Withdrawn

Post-market Evaluation of HEMOBLAST™ Bellows in Spine Surgery

Role: lead

NCT01335243Phase 2Completed

Efficacy and Safety Study of Lumbar Interbody Fusion With MatriTMBONE Associated With Autologous Bone Marrow

Role: collaborator

NCT03873181Completed

Post-Market Evaluation of HEMOBLAST™ Bellows in Laparoscopic Abdominal, Gynecological, and Urological Surgery

Role: lead

NCT03725098Not ApplicableCompleted

Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

Role: lead

NCT02502019Phase 1Completed

HEMOBLAST Pilot Clinical Investigation

Role: lead

NCT03140098Withdrawn

Evaluation of COVA™+ CARD in Adult Cardiac Surgery

Role: lead

NCT02780869Not ApplicableCompleted

HEMOBLAST Pivotal Clinical Investigation

Role: lead

NCT03770195Withdrawn

Registry Study for the Use of HEMOBLAST™ Bellows in Abdominoplasty

Role: lead

NCT03772912Withdrawn

Registry for the Use of HEMOBLAST Bellows in Total Knee Arthroplasty

Role: lead

All 10 trials loaded